

**ORION INFUSION LIMITED**  
**CONDENSED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**  
**AS AT AND FOR THE PERIOD ENDED DECEMBER 31, 2025**  
**(Half Yearly)**



**ORION INFUSION LIMITED**

**CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE SIX MONTH PERIOD ENDED DECEMBER 31, 2025 (HALF YEARLY)**

Particulars	Note	Amount in Taka			
		July to December 2025	July to December 2024	October to December 2025	October to December 2024
<b>Revenue</b>	19	<b>394,205,164</b>	<b>393,689,779</b>	<b>228,940,380</b>	<b>195,047,429</b>
Cost of Goods Sold		(234,770,154)	(232,566,541)	(138,111,240)	(115,704,917)
<b>Gross Profit</b>		<b>159,435,009</b>	<b>161,123,238</b>	<b>90,829,140</b>	<b>79,342,512</b>
<b>Operating Expenses</b>		<b>(113,440,084)</b>	<b>(113,261,193)</b>	<b>(66,286,862)</b>	<b>(56,046,902)</b>
Administrative Expenses		(17,486,093)	(17,156,407)	(10,513,532)	(8,310,193)
Selling & Distribution Expenses		(95,953,991)	(96,104,786)	(55,773,329)	(47,736,709)
<b>Profit from Operation</b>		<b>45,994,925</b>	<b>47,862,045</b>	<b>24,542,279</b>	<b>23,295,610</b>
Financial Expenses	20	(21,525,707)	(20,391,174)	(13,998,373)	(10,396,253)
Non Operating Income / (Loss)	21	6,421,902	474,431	4,910,006	377,955
<b>Net Profit from Operation</b>		<b>30,891,121</b>	<b>27,945,303</b>	<b>15,453,912</b>	<b>13,277,312</b>
Workers' Profit Participation Fund		(1,471,006)	(1,330,729)	(735,901)	(632,253)
<b>Net Profit Before Tax</b>		<b>29,420,115</b>	<b>26,614,574</b>	<b>14,718,011</b>	<b>12,645,059</b>
<b>Income Tax expense</b>	22	<b>(6,009,562)</b>	<b>(5,646,829)</b>	<b>(2,940,201)</b>	<b>(2,702,282)</b>
Current Tax	22.1	(5,884,023)	(5,322,915)	(2,943,602)	(2,529,012)
Deferred Tax Income/(Expenses)		(125,539)	(323,914)	3,401	(173,271)
<b>Net Profit After Tax</b>		<b>23,410,552</b>	<b>20,967,745</b>	<b>11,777,810</b>	<b>9,942,777</b>
<b>Add: Other Comprehensive Income</b>		<b>(1,060,354)</b>	<b>777,915</b>	<b>(1,590,778)</b>	<b>978,944</b>
Fair Value Adjustment of Marketable Securities		(1,208,101)	622,392	(1,664,651)	901,182
Deferred Tax Income/(Expense) on Revaluation Surplus on PPE		147,747	155,523	73,873	77,762
<b>Total Comprehensive Income</b>		<b>22,350,198</b>	<b>21,745,660</b>	<b>10,187,032</b>	<b>10,921,720</b>
Earning Per Share	23	<b>1.15</b>	<b>1.03</b>	<b>0.58</b>	<b>0.49</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION INFUSION LIMITED**

**CONDENSED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)  
FOR THE SIX MONTH PERIOD ENDED DECEMBER 31, 2025 (HALF YEARLY)**

Amount in Taka

Particulars	Ordinary Share Capital	Retained Earnings	Reserves	Total
<b>Balance at July 01, 2025</b>	<b>203,597,600</b>	<b>(11,887,273)</b>	<b>134,390,355</b>	<b>326,100,682</b>
Net Profit during the Period	-	23,410,552	-	23,410,552
Cash Dividend for the year 2024-2025		(24,182,720)		(24,182,720)
Fair value adjustment for sell of marketable securities	-	-	(539,550)	(539,550)
Transfer between Reserve & Retained earnings for depreciation on Revaluation surplus.	-	738,735	(738,735)	-
Fair Value Gain/(Loss) on Marketable Securities	-	-	(1,208,101)	(1,208,101)
Adjustment for deferred tax on Revaluation Surplus	-	-	147,747	147,747
<b>Balance at December 31, 2025</b>	<b>203,597,600</b>	<b>(11,920,706)</b>	<b>132,051,716</b>	<b>323,728,610</b>

**FOR THE SIX MONTH PERIOD ENDED DECEMBER 31, 2024 (HALF YEARLY)**

Amount in Taka

Particulars	Ordinary Share Capital	Retained Earnings	Reserves	Total
<b>Balance at July 01, 2024</b>	<b>203,597,600</b>	<b>(24,044,910)</b>	<b>135,070,969</b>	<b>314,623,660</b>
Net Profit during the Period	-	20,967,745	-	20,967,745
Cash Dividend for the year 2023-2024		(24,431,712)		(24,431,712)
Fair value adjustment for sell of marketable securities	-	-	145,409	145,409
Transfer between Reserve & Retained earnings for depreciation on Revaluation surplus.	-	777,615	(777,615)	-
Fair Value Gain/(Loss) on Marketable Securities	-	-	622,392	622,392
Adjustment for deferred tax on Revaluation Surplus	-	-	155,523	155,523
<b>Balance at December 31, 2024</b>	<b>203,597,600</b>	<b>(26,731,261)</b>	<b>135,216,678</b>	<b>312,083,017</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director 3

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION INFUSION LIMITED**  
**CONDENSED STATEMENT OF CASH FLOWS (UNAUDITED)**  
**FOR THE SIX MONTH PERIOD ENDED DECEMBER 31, 2025 (HALF YEARLY)**

Particulars	Note	Amount in Taka	
		July to December 2025	July to December 2024
<b>Cash Flows from Operating Activities :</b>			
<b>Receipts :</b>			
Cash received from Customers		406,167,194	379,566,560
Other Income / (Loss)		6,421,902	474,431
		<b>412,589,096</b>	<b>380,040,991</b>
<b>Payments :</b>			
Cash paid to Suppliers		(235,834,850)	(241,782,328)
Cash paid for operating Expenses		(111,649,720)	(110,219,413)
Cash paid for Financial Expenses		(21,525,707)	(20,391,174)
Income Tax paid and Deducted at Source		(5,927,967)	(12,004,887)
		<b>(374,938,243)</b>	<b>(384,397,803)</b>
<b>Net Cash Received / (Used) from Operating Activities</b>		<b>37,650,852</b>	<b>(4,356,811)</b>
<b>Cash Flows from Investing Activities :</b>			
Acquisition of Property, Plant & Equipments		-	(5,058,957)
Received from / (Payment to) Securities & Others		(663,110)	(97,980)
<b>Net Cash Received / (Used) from Investing Activities</b>		<b>(663,110)</b>	<b>(5,156,937)</b>
<b>Cash Flows from Financing Activities :</b>			
Increase/ (Decrease) in Liabilities for Other Finance		(3,477,840)	(3,476,118)
Dividend Paid		(57,247)	(345,318)
Bank Loans Received / (Repaid)		(9,178,806)	3,842,521
<b>Net Cash Received / (Used) from Financing Activities</b>		<b>(12,713,892)</b>	<b>21,084</b>
<b>Net Increase / (Decrease) in Cash &amp; Cash Equivalents</b>		<b>24,273,850</b>	<b>(9,492,664)</b>
Cash & Cash Equivalents at the beginning of the period		12,413,771	22,341,602
<b>Cash &amp; Cash Equivalents at the End of the Period</b>		<b>36,687,622</b>	<b>12,848,939</b>
<b>Net Operating Cash Flow Per Share</b>	<b>29</b>	<b>1.85</b>	<b>(0.21)</b>
<b>Number of Shares used to compute NOCFPS</b>		<b>20,359,760</b>	<b>20,359,760</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION INFUSION LIMITED**  
**Notes, comprising a summary of significant accounting policies**  
**and other explanatory information**  
As at and for the period ended December 31, 2025

**01.00 Reporting Entity**

**01.01 Background of the Entity**

Orion Infusion Limited is a public limited company incorporated in Bangladesh on 05 May 1983 and is now operating under the banner of Orion Group. The Company was converted into a public limited company on 05 October 1994. The registered office of the company "Orion House" is situated at 153-154 Tejgaon Industrial Area, Dhaka-1208, Bangladesh. Production plant of the company is situated at Maikuli, P.S.-Rupganj, and District- Naraynganj, Bangladesh.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996.

**01.02 Nature of Business**

Orion Infusion Limited is devoted in producing Large Volume Parenteral (LVP) & other lifesaving injectable products. The company has the manufacturing facilities for the production of I.V. Rehydration Solutions, Electrolyte Solutions, and Solution for Acidosis, Ranitidine I.V. infusion, Anti-Microbial products viz. Ciprofloxacin I.V., Metronidazole I.V. etc. To meet the tremendous increment of the demand of its products, Orion Infusion Ltd. is now set to expand its production capacity further by installing modern and sophisticated technologies which will certainly rich its core competence. The company is now producing pure steam generated fluids, required by GMP instead of Black steam generated fluids. Innovative product like Amino acids solution was introduced by Orion Infusion Ltd., which was the first ever manufactured in Bangladesh and this has given Orion Infusion Ltd. a competitive advantage over others. Orion Infusion Ltd. Quality Manual describes the quality policies & company wide control structure of the quality management system (QMS), which is leading towards achieving its corporate vision and mission.

**02.00 Basis of Preparation and Presentation of Financial Statements**

**02.01 Statement of Compliance**

The financial statements have been prepared in accordance with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), the Companies Act 1994, Securities and Exchange Rules 1987 and other relevant local laws as applicable.

**02.02 Components of the Condensed Financial Statements**

According to IAS-34 " Interim Financial Reporting," , these interim financial statements include the following components-

- i. Condensed Statement of Financial Position
- ii. Condensed Statement of Profit or Loss and other Comprehensive Income
- iii. Condensed Statement of Changes in Equity
- iv. Condensed Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Financial Statements

**02.03 Basis of Measurement**

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

**02.04 Functional and Presentation Currency**

The financial statements are prepared and presented in Bangladesh Taka/Tk./BDT, which is the company's functional currency. The Company earns its major revenues in BDT and all other incomes/expenses and transactions are in BDT.

**02.05 Comparative Information**

Comparative information has been disclosed in respect of the year or period for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statements.

Comparative figures have been re-arranged where considered necessary to ensure better comparability with the current period without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

#### **02.06 Reporting Period**

The Financial period of the company covers from July 01, 2025 to December 31, 2025.

#### **02.07 Use of Estimates and Judgments**

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

#### **02.08 Materiality, Aggregation and Off setting**

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the company has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of any asset or liability as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

#### **02.09 Going Concern Review**

As per IAS-1, a company is required to make assessment at the end of each year to make assessment of its capability to continue as going concern. Management of the company makes such assessment each year. The company has adequate resources to continue its operation for the foreseeable future and has wide coverage of its liabilities. For this reason, the directors continue to adopt going concern assumption while preparing the financial statements.

#### **02.10 Date of Authorization**

The financial statements were authorized for issue by the Board of Directors in its meeting held on January 29, 2026 for publication.

#### **03.00 Accounting Policies and Methods of Computations**

##### **IFRS-16: Leases**

In January 2016, the International Accounting Standards Board (IASB) issued IFRS-16 which is effective from annual reporting period beginning on or after 1 January 2019. The company has applied IFRS-16 Leases for the first time with the date of initial application of 01 July 2019.

IFRS 16 introduces new or amended requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance lease and requiring the recognition of a right-of-use asset and a lease liability at commencement for all leases.

The Company has applied IFRS 16 using the modified retrospective approach and therefore the comparative information has not been restated.

#### **04.00 Subsequent Events**

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

Note	Particulars	Amount in Taka	
		31.12.2025	30.06.2025
<b>05.00</b>	<b>Property, Plant and Equipment</b>		
	<b>A) At Historical Cost</b>		
	Opening Balance (At Cost)	665,351,425	659,561,953
	Add: Addition during the Period	-	5,789,472
	Less : Disposal during the Period	-	-
		<b>665,351,425</b>	<b>665,351,425</b>
	Opening Balance of Depreciation	467,150,686	456,303,041
	Charged during the Period	5,104,175	10,847,645
	Less : Disposal during the Period	-	-
	<b>Accumulated depreciation</b>	<b>472,254,861</b>	<b>467,150,686</b>
	<b>Written down value</b>	<b>193,096,565</b>	<b>198,200,740</b>
	<b>B) At Revaluation</b>		
	Opening Balance	166,981,322	166,981,322
	Add: Addition during the Period	-	-
		<b>166,981,322</b>	<b>166,981,322</b>
	Less: Depreciation		
	Opening Balance of Depreciation	19,409,984	17,854,753
	Charged during the Period	738,735	1,555,231
	<b>Accumulated depreciation</b>	<b>20,148,718</b>	<b>19,409,984</b>
	<b>Written down value</b>	<b>146,832,604</b>	<b>147,571,338</b>
	<b>Total Carrying Value (A+B)</b>	<b>339,929,168</b>	<b>345,772,078</b>
<b>06.00</b>	<b>Right-of-use Assets</b>		
	<b>A) At Historical Cost</b>		
	Opening Balance (At Cost)	66,297,800	57,195,190
	Add: Addition during the Period	1,136,562	9,102,610
		<b>67,434,362</b>	<b>66,297,800</b>
	Less: Disposal/ Adjustment	-	-
		<b>67,434,362</b>	<b>66,297,800</b>
	Opening Balance of Depreciation	52,254,426	45,431,018
	Charged during the Period	3,380,147	6,823,408
	<b>Accumulated depreciation</b>	<b>55,634,573</b>	<b>52,254,426</b>
	<b>Written down value</b>	<b>11,799,789</b>	<b>14,043,374</b>
<b>07.00</b>	<b>Investments</b>		
	Investment in Non-quoted Shares	16,825,396	16,825,396
	Investment in Marketable Securities	5,344,007	6,439,895
	Fixed Deposit (FDR), Agrani Bank, WASA Branch	399,980	388,633
		<b>22,569,383</b>	<b>23,653,924</b>

**07.01 Investment in Non-quoted Shares**

ICB Islamic Bank Ltd.

16,825,396	16,825,396
<b>16,825,396</b>	<b>16,825,396</b>

**07.02 Investment in Marketable Securities**

	31.12.2025		30.06.2025	
	Market Price	Cost Price	Market Price	Cost Price
<b>A. Southeast Bank Capital Services Ltd.</b>				
Sandhani Life Ins. Company Ltd.	970,000	1,757,680	545,950	1,297,726
Aftab Automobiles Ltd.	-	-	1,480,000	1,853,810
Monno Ceramic Industries Ltd.	-	-	2,970,000	3,031,839
Associated Oxygen Limited	-	-	87,600	234,217
Sea Pearl Beach Resort & Spa Limited	3,048,100	5,311,676	-	-
	<b>4,018,100</b>	<b>7,069,356</b>	<b>5,083,550</b>	<b>6,417,593</b>

**B. Bank Asia Securities Ltd.**

Premier Leasing & Finance	11,907	387,419	63,945	387,419
Eastern Housing Limited	1,314,000	2,263,745	1,292,400	2,263,745
	<b>1,325,907</b>	<b>2,651,163</b>	<b>1,356,345</b>	<b>2,651,163</b>
	<b>5,344,007</b>	<b>9,720,519</b>	<b>6,439,895</b>	<b>9,068,756</b>

**08.00 Inventories**

Raw Materials	35,020,527	45,603,008
Packing Materials	35,609,700	44,179,219
Work - in - process	1,139,131	6,958,902
Finished Goods	14,554,275	13,986,143
Promotional Materials	3,931,231	4,315,761
Printing & Stationeries	4,567,914	4,176,748
Goods in Transit	31,516,335	9,814,081
	<b>126,339,112</b>	<b>129,033,862</b>

**09.00 Trade and other receivables**

Accounts Receivables	141,317,427	153,279,458
	<b>141,317,427</b>	<b>153,279,458</b>

This is unsecured, considered good and is falling due within one year. Classification schedule as required by schedule XI of Companies Act 1994 are as follows:

**Aging of the above balance is as follows:**

Below 180 days	141,317,427	153,279,458
Above 180 days	-	-
	<b>141,317,427</b>	<b>153,279,458</b>

Particulars	Amount in Taka	
	31.12.2025	30.06.2025
I. Accounts Receivable considered good in respect of which the company is fully secured	141,317,427	153,279,458
II. Accounts Receivable considered good in respect of which the company holds no security other than the debtor personal security	-	-
III. Accounts Receivable considered doubtful or bad	-	-
IV. Accounts Receivable due by any director or other officer of the company	-	-
V. Accounts Receivable due by Common Management	-	-
VI. The maximum amount of receivable due by any director or other officer of the company	-	-
<b>Total</b>	<b>141,317,427</b>	<b>153,279,458</b>

As at December 31, 2025 the company did not make any provision against trade receivables as there as no indication of impairment.

#### 10.00 Advances, Deposits & Prepayments

##### Advances

Advance Income Tax	<b>Note - 10.01</b>	145,716,279	139,788,311
Travel and Other Advances		352,346	400,263
Advance paid to Suppliers		12,522	245,272
Advance for Office Rent		961,144	956,304
Motor Cycle & Car Advance		29,317	78,023
Advance against C&F		11,758,175	14,616,589
Advance Against Cash Purchase		10,350	38,000
		<b>158,840,133</b>	<b>156,122,763</b>

##### Deposits

Security Deposit	6,393,328	6,393,328
Bank Guarantee	3,376,793	3,376,793
Earnest Money	654,840	654,840
Collection & Other Advance	1,604,081	2,061,289
L/C Margin & Balance	1,067,680	428,400
	<b>13,096,722</b>	<b>12,914,650</b>
	<b>171,936,855</b>	<b>169,037,412</b>

#### 10.01 Advance Income Tax

Opening Balance	139,788,311	119,891,670
Income tax paid during the period	5,927,967	19,896,641
	<b>145,716,279</b>	<b>139,788,311</b>

#### 11.00 Cash and Cash Equivalents

<b>Cash in Hand</b>	<b>1,056,173</b>	<b>1,377,744</b>
(a) Cash in Hand/Imprest Cash	943,534	1,189,501
(b) Balance at Brokerage House	112,639	188,243
<b>(c) Cash at Bank</b>	<b>35,631,449</b>	<b>11,036,028</b>
Current Account (Main)	7,745,081	7,764,716
Current Account (Collection)	1,639,089	1,089,471
Short Term Deposit Account	26,247,279	2,181,841
<b>Total</b>	<b>36,687,622</b>	<b>12,413,771</b>

Note	Particulars	Amount in Taka	
		31.12.2025	30.06.2025

## 12.00 Share Capital

### a) Authorized Capital

100,000,000 Ordinary Shares of Taka 10/- each 1,000,000,000 1,000,000,000

### b) Issued, Subscribed and Paid-up Capital

20,359,760 Ordinary Shares of Taka 10/- each 203,597,600 203,597,600

### c) Distribution Schedule

The detailed schedule showing the number of shareholders and their shareholding in percentage has been disclosed below as a requirement of the Regulation 37(3) of Dhaka Stock Exchange and Chittagong Stock Exchange.

Range of holding in number of shares	No. of Shareholders	Number of Shares held	Percentage of Shareholding 31.12.2025	Percentage of Shareholding 30.06.2025
Up to 500 shares	5,395	859,627	4.22%	4.48%
501 to 5,000 shares	1,690	2,546,814	12.51%	14.34%
5,001 to 10,000 shares	128	932,100	4.58%	4.96%
10,001 to 20,000 shares	73	1,073,893	5.27%	6.01%
20,001 to above	106	14,947,326	73.42%	70.21%
<b>Total</b>	<b>7,392</b>	<b>20,359,760</b>	<b>100%</b>	<b>100%</b>

### d) Shareholding Position as on December 31, 2025 is as follows:

Composition of Shareholding	No. of Shareholders	Number of Shares held	Percentage of Shareholding 31.12.2025	Percentage of Shareholding 30.06.2025
Sponsors	4	8,268,400	40.61%	40.61%
Foreign Investors	26	9,248	0.05%	0.06%
Institutional	207	2,564,630	12.60%	13.09%
General Public	7,155	9,517,482	46.75%	46.24%
<b>Total</b>	<b>7,392</b>	<b>20,359,760</b>	<b>100%</b>	<b>100%</b>

## 13.00 Reserves

Revaluation surplus on PPE	<b>Note: 13.01</b>	136,428,228	137,019,216
Fair value changes in investment	<b>Note: 13.02</b>	(4,376,512)	(2,628,861)
		<u>132,051,716</u>	<u>134,390,355</u>

### 13.01 Revaluation surplus on Property, plant and equipment

<b>Opening Balance</b>	137,019,216	138,263,400
Depreciation on revalued asset	(738,735)	(1,555,231)
Adjustment for deferred tax on Revaluation Surplus	147,747	311,047
	<u>136,428,228</u>	<u>137,019,216</u>



Note	Particulars	Amount in Taka	
		31.12.2025	30.06.2025
<b>16.00</b>	<b>Short Term Loans</b>		
	Agrani Bank C.C. (Hypothecation) - 54566, WASA Branch	213,628,898	206,647,053
	Agrani Bank (LTR), WASA Branch- 4786	82,934,916	99,095,567
		<b>296,563,814</b>	<b>305,742,620</b>
<b>17.00</b>	<b>Trade and other payables</b>		
	Trade Payables	46,536,482	55,547,873
		<b>46,536,482</b>	<b>55,547,873</b>
<b>18.00</b>	<b>Accrued Expenses</b>		
	Utilities	1,804,144	1,663,783
	Salary and Wages	11,925,109	14,696,311
	Employee Benefit Payable	6,491,120	7,449,787
	Audit Fee	-	383,333
	Corporate Governance Audit Fee	69,000	69,000
	Provision for Income Tax	78,425,362	72,541,339
	Others payable	2,331,928	2,097,351
		<b>101,046,663</b>	<b>98,900,905</b>
<b>18.01</b>	<b>Provision for current tax</b>		
	Opening Balance	72,541,339	64,485,260
	Add: Provision made during the period	5,884,023	8,056,079
		<b>78,425,362</b>	<b>72,541,339</b>
<b>19.00</b>	<b>Revenue</b>		
	Local Sales	394,205,164	393,689,779
		<b>394,205,164</b>	<b>393,689,779</b>
<b>20.00</b>	<b>Financial Expenses</b>		
	Interest on C.C. (Hypo), Agrani Bank Ltd.	14,113,342	13,268,401
	Interest on LTR Loan Agrani Bank Ltd.	6,631,679	6,533,548
	Finance Cost (Lease Obligation-Office Rent)	780,686	589,225
		<b>21,525,707</b>	<b>20,391,174</b>
<b>21.00</b>	<b>Non Operating Income</b>		
	Other Income	5,641,413	416,604
	Bank Interest	24,442	22,976
	Interest on FDR	13,349	9,412
	Capital Gain/(Loss) on Marketable Securities	539,550	(145,409)
	Dividend Income	203,148	170,848
		<b>6,421,902</b>	<b>474,431</b>

## 22.00 Income Tax Expense

Current Tax on profit for the Period	Note - 22.01	5,884,023	5,322,915
Deferred tax expense/(income)		125,539	323,914
		<b>6,009,562</b>	<b>5,646,829</b>

Particulars	Taxable Income	Taxable Amount	
		31.12.2025	31.12.2024
Tax on taxable profit	29,216,967	5,843,393	5,288,745
Tax on dividend income	203,148	40,630	34,170
<b>Total</b>	<b>29,420,115</b>	<b>5,884,023</b>	<b>5,322,915</b>

### Minimum Tax

#### Calculation of gross receipt

##### Revenue:

Sales	394,205,164	393,689,779
Other Income	5,641,413	416,604
Interest on FDR	13,349	9,412
Capital Gain/(Loss) on Marketable Securities	539,550	-
<b>Total Gross Receipts</b>	<b>400,399,475</b>	<b>394,115,795</b>
Minimum Tax (.60% On Total Gross Receipts)	<b>2,402,397</b>	<b>2,364,695</b>

Disclosures as per BSEC NOTIFICATION No. BSEC/CMRRCD/2006-158/208/ADMIN/81 Dated 20 June, 2018

## 23.00 Earning Per Share (EPS)

The computation is given below

Net Profit After Tax	23,410,552	20,967,745
Ordinary shares outstanding during the Period	20,359,760	20,359,760
	<b>1.15</b>	<b>1.03</b>

## 24.00 Acquisition of Property Plant & Equipments during the period

SL. NO.	Particulars	Amount in Taka	
		31.12.2025	31.12.2024
1	Plant & Machinery	-	2,568,426
2	Office Equipment	-	2,490,531
	<b>Total</b>	<b>-</b>	<b>5,058,957</b>

Note	Particulars	Amount in Taka	
		01.07.2025 to 31.12.2025	01.07.2024 to 31.12.2024

**25.00 Reconciliation of net profit with cash flows from operating activities**

<b>Net Profit before tax</b>	<b>29,420,115</b>	<b>26,614,574</b>
Interest & other income	(6,421,902)	(474,431)
Financial Expenses	21,525,707	20,391,174
(Increase) /Decrease in accounts receivables	11,962,030	(14,123,219)
Increase in Inventory	2,694,749	(8,013,262)
Increase / (Decrease) in trade payable	(9,011,392)	(7,880,218)
Increase / (Decrease) in accrued expenses	(3,738,265)	(3,400,072)
Depreciation	9,223,057	10,723,861
Increase in Advance, Deposit & Prepayments	3,028,525	3,726,412
<b>Cash generated from operating activities</b>	<b>58,682,624</b>	<b>27,564,819</b>
Investment Income	6,421,902	474,431
Finance Cost paid	(21,525,707)	(20,391,174)
Income taxes paid	(5,927,967)	(12,004,887)
<b>Net cash flows from operating activities</b>	<b>37,650,852</b>	<b>(4,356,811)</b>

**26.00 Calculation of Net operating cash flow per share (NOCFPS)**

Net Cash flow from operating activities	37,650,852	(4,356,811)
No. of Shares	20,359,760	20,359,760
Net operating cash flow per share (NOCFPS)	<b>1.85</b>	<b>(0.21)</b>

NOCFPS increased to 1.85 from (0.21) of the previous corresponding period. During the period cash received from customer is increased than the previous corresponding period.

**27.00 Calculation of Net Asset Value Per Share**

	850,579,356	847,233,879
Total Assets	526,850,746	521,133,198
Total Liabilities	<b>323,728,610</b>	<b>326,100,682</b>
Net Assets	20,359,760	20,359,760
No. of Share	<b>15.90</b>	<b>16.02</b>
<b>Net Asset Value (NAV) Per Share</b>		

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary